**Marine-Derived Natural Products: A Novel Source of Potential Anticancer Drugs in the Ocean**

 **KharadS. D.1\*,** Sole S. D.1, Thorat R. B.1, Pawar A. R.1, Pandhare R. B.1, Deshmukh

V. K.1, Mohite P. B.2

1MES’s College of Pharmacy, Sonai, Newasa, Ahmednagar, Maharashtra, India.

2A.E.T’s St. John Institute of Pharmacy and Research, Manor Road, Palghar, Maharashtra, India.

**For correspondence - Kharadsharayu01@gmail.com**

**Abstract**

Cancer continues to rank among the deadliest diseases in the world. Living organisms have been studied for potential cancer treatments due to the need for new drugs. By using molecular modeling and chemical synthesis, it has been discovered that the marine environment is a rich source of chemicals with unique chemical properties that can be applied to improve the specificity, effectiveness of cutting-edge medications. Many unique bioactive metabolites with various chemical structures have been found in marine populations. This overview includes information on marine plants, bacteria, algae, sponges, fungi, soft coral, and actinomycetes, with an emphasis on the last two. Studies on marine natural products' capacity to fight cancer as well as their effectiveness in suppressing tumors, compound-induced apoptosis, and cytotoxicity were initially studied in connection to in vitro and in vivo research. It is also covered how the biological effects are supported by molecular processes. In this work, we highlight the variety of marine species, as well as the inventiveness of chemical structures and chemical property space. The usage of components obtained from marine sources, treatment methods, and discussions of their potential future uses as anticancer drugs are also included.

**Keywords:** anticancer, drugs, marine-derived products, drugs, microorganism, antitumor,

**1. Introduction**

One of the worst diseases in the world is still cancer [1]. The planet's surface is covered by water on a 70%+ basis. The oceans are the most beautiful area on Earth, they are home to a wide diversity of marine and freshwater organisms, as well as more natural and biochemical mixing [1]. On the other hand, several FDA-approved medications have been obtained via terrestrial means. Nonetheless, increased marine sources have recently yielded a slew of complexes, anticancer drug candidates, and a slew of significant metabolites. There are about 30,000 natural resource blends of marine origin. Each year since 2008, more than 1,000 complexes have been erected. In addition, structural categorization breakthroughs, randomness, and diversity are frequently used to characterize these complexes [2]. Obtaining vital drugs to treat various cancers and diseases requires access to marine sources. Researchers scoured the seas and oceans for aquatic organisms that created mixes that may be used in clinical and therapeutic settings. Seaweeds, enormous mangroves, sponges, and microbes are among the aquatic life species that have joined them [3]. Anticancer drugs and natural substances derived from the sea have a variety of applications in the treatment of different malignancies as well as cancer itself. MNPs can be used to revive important pharmacological mediators, such as naturally occurring immune agents, chemically produced combinations, or chemical complexes [4]. Cancer death rates remain high despite a lack of focus on significant research initiatives, including fresh clinical ideas employing cutting-edge therapeutics[5]. The majority of anticancer pharmaceutical markets around the world rely on natural resource-derived components and metabolites generated by engineering processes, which include mixes derived from organisms living in the marine environment [6]. As a result of advances in biology and immunotherapy research, as well as significant advancements in current medication design and production, cancer cure research has become a viable goal. [7].

Lymphomas, testicular cancer, and juvenile lymphoblastic leukemia are only a few of the human cancers that have been cured or have had their survival durations prolonged [8–10]. Despite substantial breakthroughs in existing therapies [11,12],  chemotherapy has been associated with several side effects [13], spurring a search for a more effective solution with fewer side effects [14]. Natural products have the potential to be exploited in the development of new drugs, drug candidates, and chemical entities [15,16]. Bioactive natural products are used in around 80% of licensed chemotherapeutic treatments [17], while bioactive natural products are used in more than half of all drugs [18]. Natural products are used to treat 87 percent of human ailments, including cancer. [19], which is widespread. Natural bioactive compounds that target cancer-causing macromolecules, such as those implicated in oncogenic signal transduction pathways, have been shown to induce cancer [20–22] In the late 1800s, the term "marine" first appeared. Biotechnology evolved after 1980 into a science that focused marine research on applications such as medical development[23].. This investigation is still being conducted, and cutting-edge technology is being used. [24]. There is growing interest in using the variety and complexity of marine natural product scaffolds, given their tremendous potential, to create intelligent medications.We discussed marine-derived compounds that may have anticancer properties.

**2. Marine-derived natural products and their classification**

Up until 2008, marine invertebrates were the primary source of new compounds discovered in marine creatures; Marine invertebrates of the phylum Porifera (mostly sponges) and Coelenterate provided more than 75% of these chemicals (mostly coral).This percentage stayed the same between 1985 and 2008.[25]. As coral grows in the tropical ocean, which has the highest biodiversity, and sponges are found in the most diverse environments worldwide, the majority of new compounds have been found in coral and sponges. The world's oceans are vast, and marine creatures serve as the foundation for both a vast array of chemical component clusters and innovative anticancer medicines. The separation and blending of various chemical combinations of marine origin for cancer therapy is done utilizing developed techniques. [26]. Marine natural products can be divided into seven groups based on their chemical composition: Alkaloids, strigolactones, ethers (including ketals), phenols (including quinones), terpenoids, steroids (including steroidal saponins), and peptides [27]. In any case, marine sources for anticancer drugs remain underutilized. The most noteworthy MNPs include a variety of created classes of marine alkaloids, terpenes with a wide range of structural diversity, peptides from various marine creatures, polyketides with unique biological properties, and high molecular weight organic sugars (Table 1).All of these types of MNPs are essential in the development of anticancer drugs because of their strong natural defenses against potentially lethal infections.of MNPs are crucial in the creation of anticancer medicines [28,29].

**3. Mechanisms for the Anticancer Activity of Marine Plants**

A global search for cutting-edge drugs that are deadly to cancer cells but innocuous to healthy cells has been prompted by the expansion of cancer registries. In addition to the tumor cells, the normal cells in the area of the body where the cancer had grown were also relatively dangerously affected by the anticancer treatments previously used. These days, the search for new anticancer drugs uses both terrestrial and marine habitats. [30]. DNA repair enzymes are able to undo the bulk of the harm. Age increases the risk of cancer and oxidative DNA damage [31].

**3.1. Antioxidants**

Marine creatures that are continually exposed to environmental stresses and changes need on antioxidant molecules to maintain cellular redox equilibrium and to survive. [32]. By oxidizing specific intracellular chemical moieties, antioxidants can lead to genetic changes and the activation of metabolic pathways that encourage proliferation and neoplastic transformation. [33]. As a result of their differing oxidant targets or cellular compartmentalization, several defenses work best together [34]. Under normal conditions, large levels of SOD prevent the formation of peroxynitrite. Additionally, glutathione levels are decreased by the antioxidant (GSH). GSH is composed of amino acids containing sulfhydryl groups and is required for intermediate antioxidant metabolism [35]. The right kind of nourishment supports the body's built-in enzymatic defenses against free radicals.These enzymes' structure and catalytic activity are affected by a number of essential minerals, including manganese, selenium, zinc, and coper [36]. Vitamin E has not been linked to any enzyme system's functionality, in contrast to other vitamins [37]. The only known function of this compound is that of an antioxidant and free radical scavenger, which makes it a superb lipid and phospholipid membrane defender [38]. Gene expression is regulated by vitamin E, and it also lessens inflammatory responses, among other effects. It has been demonstrated that ascorbate is a potent ROS scavenger for singlet oxygen, hydroxyl radicals, hydrogen peroxide, and superoxide radical anion. [39,40]. Vitamin C also protects target molecules from nitrosation by scavenging reactive nitrogen oxide species [41]. By absorbing another hydrogen atom, the ascorbyl free radical can be reduced to ascorbate or further oxidized to dehydroascorbate [42]. A recycling system for vitamin C has been developed as a result and works similarly to the vitamin E system. Free radicals are produced during tissue metabolism, but they can only do so much damage before being neutralized by the cell's antioxidant defenses and repair mechanisms. If a person is healthy and gets enough nutrients, there won't be much tissue damage since metabolically active tissue cells are more likely to repair any damage that does occur. [43]. Despite the fact that many different types of marine plants are employed in food and pharmaceuticals, their antioxidant and anticancer properties have yet to be investigated [44].

Researchers are invited to present recent findings and novel research on a wide range of topics related to the evolution of emergent marine antioxidant biosynthesis, the functional and ecological roles of these molecules in the ocean, biotechnological production, and potential applications of these molecules as new medications, dietary supplements, and healthcare products in this Special Issue.[32]. According to epidemiological research, consuming a lot of plant-based foods that are rich in antioxidants may help prevent cancer. Many antioxidants, both natural and synthetic, have been shown to slow the chemical carcinogenesis in test animals. In addition to a diet high in vegetables and fruits, some prospective research on the effects of supplemental antioxidants, such as vitamin E, vitamin C, selenium, and carotenoids, might be proposed for the maintenance of health and the prevention of disease. [45].

**3.2. Immunomodulation and Apoptosis**

Since they specifically target tumor cells, tumor neovasculature, and host negative immunoregulatory components, MAbs have become effective immunotherapeutic agents against cancer (checkpoints). However, to effectively use anticancer vaccines that actively modulate the immune response, it will be necessary to identify the proper tumor-rejection antigens, enhance interactions between peptides, antigen-presenting cells, and T cells, and block any adverse immunological checkpoints that obstruct a productive immune response. [46]. Apoptosis is a multi-step process in which dying cells undergo a number of changes. Several signaling pathways are involved. When the balance of anti- and proapoptotic proteins shifts, the apoptotic machinery is activated. Antiapoptotic proteins are upregulated, proapoptotic proteins are downregulated, and caspase synthesis is lowered, all of which can limit apoptosis [47]. In cancer-causing conditions marked by a lack of apoptosis, dysregulation of apoptotic signaling may be involved [48]. Activating the mitochondrial apoptosis pathway and acting as a death receptor, caspase 8 is also responsible for Cytochrome C emidsion. An example of an effector caspase is caspase 3, which destroys proteins necessary for cell survival to kill cells [49]. Inducing apoptosis is one of the most effective ways to halt cancer cells from reproducing. Radiation and apoptosis-inducing medicines, such as tamoxifen, have been used to treat cancer [50,51]. Apoptosis is a process through which several chemopreventive medications work to prevent cancer [52]. Plant extracts may induce apoptosis by increasing the number of macrophages, enhancing immune surveillance, and turning on signal complexes that trigger death [53]. Phytochemicals from the sea can also activate macrophages, causing them to perish. Fucoidan, an immunomodulator derived from Laminaria japonica, acts directly on macrophages and T cells, restoring immunological function in immunocompromised mice [54]. It may also aid in the recovery of immune function in irradiated mice [55,56]. Fucoidan may boost the in vitro synthesis of interferon and interleukin-1 (IL-1) (IFN)) [57]. The percentage of murine cytotoxic T cells increases when high-weight fucoidan produced from Okinawa mozuku is used. [58].) [59]. This might cause macrophage polarization to shift from M2 to M1, which might then cause H2O2 to regenerate and increase the IMSN nanozyme's catalytic activity. Both in vivo CT26-tumor-bearing mouse models and in vitro multicellular tumor spheroids were used (MCTS), the anticancer impact of IMSN-PEG-powerful TI has been demonstrated. A potential method to eradicate cancer cells is the tumor treatment method based on nanozymes with immunomodulation enhancement [60].

**3.3. Nutritional Values and Anticancer Effects**

Because it provides vital ecological services, marine biodiversity is an important resource for human society. In one of the strangest ecosystems, this web supports hundreds of unique species of bacteria, fungi, and viruses that participate in a variety of ecological and biochemical processes. Because the marine ecology is so diverse, every drop of ocean water contains nine out of ten microorganisms that we don't know about. [61]. The needs of humans for food, nutrition, and the treatment of ailments are all met in large part by marine plants. Diets for cancer prevention primarily consist of plant-based foods. The risk of cancer has been linked to increased consumption of a wide range of plant foods. There is evidence that certain cancers can be prevented by eating non-starchy vegetables and fruits. [62]. Seaweeds are consumed by humans and have been used traditionally to treat a number of disorders. They include a wide range of intriguing components (arthritis, tuberculosis, influenza, colds, cancer, etc.). The majority of people inadvertently ingest seaweed products every day in the form of processed foods like fruit , meat, and dairy as well as household goods like cosmetics, paint, solid air freshners, toothpaste and other similar items.,Vitamins B1, B12, A, C, E, and D, niacin, riboflavin, folic acid 3, 4, pantothenic acid, and minerals Na, Ca, K, and P are all abundant in seaweeds. The majority of the essential amino acids for life and welfare are present in them, providing a well-balanced amino acid profile.They contain far more trace elements than vegetables and other terrestrial plants, including over 54 essential for human physiological activities [63,64]. With their favorable physiological effects, therapeutic qualities, and additional health benefits like anticancer or anti-inflammatory activity, the potential for marine-derived minerals and other marine bioactive components as functional food additives is enormous [65]. Appropriate animal models must be employed for the investigation in order to show how these chemicals work. The sea cucumber is a top candidate for drug discovery since it is a rich source of bioactive chemicals, even if much more research is required in this area. The majority of the time, isolated drugs have only been evaluated in extremely modest concentrations and in conjunction with different substances [66].

**4. Nature and Cancer Chemotherapy**

Natural goods have been enormously successful in contemporary civilization. Because secondary metabolites from plants and microbes were used, our life expectancy more than doubled in the 20th century. By enabling organ transplantation, they have revolutionized medicine by easing suffering and anguish. Since the chemical variety of a region depends on its biological and geographical richness, researchers look at the entire globe while bioprospecting. [67]. Many organic substances derived from plants and marine microorganisms have been shown to be beneficial in the treatment and prevention of cancer over the past 50 years (Table 1). [68,69]. Invertebrates, terrestrial bacteria, animals, plants, and plants all contribute to the development of anticancer drugs. Taxol, an antineoplastic therapy derived from the bark of the Western Yew tree, has been discovered to be effective in the treatment of breast cancer when combined with the active complex alkaloid medications Vinblastine and Vinblastine [70]. They have been shown to be useful in the treatment of juvenile leukemia, Hodgkin's disease (lymphocytic cancer), and choriocarcinoma [71]. The National Cancer Institute gives scientists the resources they need to learn more about how diet and nutrition affect cancer prevention, but research into cancer chemoprevention using marine natural compounds is still in its infancy [72,73] has not been adequately examined, and there is a dearth of preclinical and clinical evidence on this method [74]. Anticancer chemicals have been discovered and developed using plants, microorganisms, and marine animals. As a consequence, numerous natural products are now being researched in preclinical studies, and 14 natural products originating from osanic creatures are undergoing clinical trials at different stages, demonstrating the promise of marine natural chemicals [75]. Using marine resources, a concentrated, combinatorial strategy has been suggested as a means to accelerate the creation of novel anti-cancer medications with higher efficacy and fewer adverse effects [76,77]. Finding novel medicines continues to rank highly in the priority list for cancer therapy due to the rapid rise in chemotherapeutic drug resistance. The demand for innovative anti-tumor drugs that work against incurable malignancies and have therapeutic efficacy while having fewer side effects or less toxic adverse effects is further increased by the high toxicity frequently associated with existing cancer chemotherapeutic therapies [78].

**Table 1:** **The list of marine-derived substances that may have anticancer properties follows.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Compound Name/Class** |  **Source** | **Cancer type** | **Mechanism** | **Ref.** |
| Apratoxin A/Peptide | Bactaria, yngbya boulloni | Cervical cancer | Cell cycle inhibition IC50 = 2.2 nM | [79] |
| Brugine/Alkaloid | Plants, bruguiera sexangula | Lewis and Sarcoma 180  | not disclosed | [64] |
| Fucoidan/Polysaccharides | Algea, ascophyllum nodosum | Colon cancer | At conc. of 80 to 100 µg/mL prevent the growth of arterial smooth muscle cells. | [80] |
| Lyngbyabellin B/p Peptide | Bacteria, lyngbya majuscule | Burkitt lymphoma cancer | Supression of cell growth IC50 = 0.02 µM | [81] |
| Sansalvamide A/Peptide | Marine fungi | Pancreatic, breast, colon, and prostate cancers | Hinders the synthesis of protein complexes | [81] |
| Phlorofucofuroecol A/Polyphenol | Brown seaweeds | Cancer | not disclosed | [82] |
| Phloroglucinol/polyphenol | Brown seaweed | Colon cancer | Cause cell death at 300 µM and DNA damage | [83] |
| Chondroitin-4-sulphate/Polysaccharides | Sea cucumber, Cucumaria frondosa, |  | Not disclosed | [64,84] |
| Chondroitin-6-sulphate/Polysaccharides | Sea cucumber, Cucumaria frondosa, |  | Not disclosed | [64,84] |

**7. Anticancer Bioactive Antibiotics Derived from Marine Sources**

Biologically active substances with a variety of modes of action, including antiproliferative, antioxidant, and antimicrotubule properties, have been created, in particular, by sea algae and cyanobacteria. Due to the finding of their secondary metabolites in sponges, ascidians, tunicates, and mollusks, peptides from marine animal sources have recently attracted interest [85], antibiotics with bioactive anticancer agents. This product was made with marine resources. The majority of these medications focus on elements of universal signal transduction pathways [86]. Antitumor antibiotics, such as anthracyclines, 26/64 actinomycin, and aureolic acid, are among the most commonly used cancer chemotherapeutic medicines [87,88]. Actinomycin D may target numerous tumour metabolic regulators as a new anti-glioma strategy by targeting peptididolides, dactinomycin, and other clinically useful agents from these families, which were discovered to downregulate a number of glioma metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis (Figure 3, Figure 8, and Table 2) [89]. Antitumor antibiotics that block topoisomerase II are among the most commonly used [90–92]. Geldanamycin is a naturally occurring benzoquinone ansamycin fermentation product that inhibits HSP90 in HeLa cells and causes cytotoxicity [93,94]. The trabectedin complex's mode of action was aided by the three fused tetrahydroisoquinoline rings. The chemical structure, according to the researchers [95], interacts directly with transcription factors like SP-1 to impede important links between DNA and transcription by binding covalently to DNA's minor groove. Bryostatin is another chemotherapeutic drug that modifies the paclitaxel-induced protein kinase C inhibitor (PKC) [96]. The anticancer medication bryostatin 1, produced from the bryozoan Bugula neritina, can trigger Bcl-2 ubiquitination and proteasome breakdown, allowing lymphoblastic leukemia bone marrow progenitor cells to grow [97]. Bryostatins are protein kinase C (PKC) activators that regulate cell proliferation, differentiation, and activation [98]. Cell cycle arrest, protein synthesis inhibition, and antiangiogenic activity similar to didemnin B and aplidine are all proposed mechanisms [99,100]. Plinabulin (NPI-2358), a highly selective and powerful vascular disrupting agent (VDA) derived from a marine fungus extract, is now in phase II clinical studies [101] owing to its efficacy against multidrug-resistant human tumour cell lines. [102]. Antileukemic activities have been shown for the penicillium chrysogenum alkaloid sorbicillactone-A, which is found in the marine sponge Ircinia fasciculate [103]. Depsipeptide (NSC 630176), a bicyclic peptide derived from Chromobacterium violaceum, inhibited a histone deacetylase and reduced c-MYC expression, causing cell cycle arrest in the G0-G1 phase. [104]. In recent years, lead compounds identified for various pharmaceutical uses have been largely sourced from marine sources. It's interesting to note that marine microorganisms continue to be the source of several crucial and little-known bioactive metabolites. Microorganisms occupy an extensive stretch of the biosphere, ranging from the shallow water along the beach to the abysmal seaward regions that cover 70% of it. [105]

**7.1. Polysaccharides**

More and more commonly, polysaccharides are being employed as building blocks for the development of nanoscale drug delivery systems. This is accounted for by the exceptional qualities of polysaccharides, such as their biodegradability, biocompatibility, low toxicity, and low cost [106]. Another prominent chemical family found in many marine species is polysaccharides, which include alginates, agar, and carrageenans [64]. (Figure 5; Table 1). Polysaccharide cytotoxicity is predominantly mediated by innate immune system stimulation [107], it causes the creation of tumor-crushing cytokines, the activation of natural killer cells and macrophages, and their migration to the target site [108,109]. Internally sulfated glycosaminoglycans caused the death of mice melanoma cells by changing their transcription [110,111] This effect was discovered to be caused by caspase-3 activation and subsequent downregulation of the kinase pathway [112,113] Many different types of polysaccharides found in sea creatures have intriguing biological traits with human GAGs. Fucoidans and their LMW forms, among other algal polysaccharides, may serve as one of the primary sources of polysaccharides for cell therapy and regenerative medicine in the future. [114].

**7.2. Alkaloids**

There are four different categories of marine alkaloids: indoles, phenylethylamines, halogenated indoles, and other alkaloids. (Figure 6; Table 1), most of which are phenylethylamines and indoles [64,115] Alkaloids such as brugine, acanthicifolin, and benzoquinones are found in Bruguiera sexangula, Acanthus illicifolius, and Kandelia candel. [64]. The alkaloid "rhizophorrine" is found in Rhizophora mucronata and Rhizophora stylosa, two mangrove species found on the beaches and river banks of East Africa and the Indo-Pacific region. A range of cancer cell types has been demonstrated to be inhibited by these compounds.

**7.3. Polyphenols**

Polyphenols include catechin, phenolic acids, tannins, flavonoids, anthocyanidins, gallic acid, epicatechin gallate, epigallate, and gallic acid, in addition to lignin, epigallocatechin gallate, epicatechin gallate, gallic acid, and epigallate (Table 1) [116]. It has been demonstrated that polyphenolic substances lower cellular protein levels and the mitotic index, both of which are necessary for the proliferation and colony formation of cancer cells. Because of its cytotoxic properties, scutellarein 4'-methyl ether, for instance, has anticancer activity both in vitro and in animals. Along with having anticancer properties, phenols also have anti-inflammatory, antiviral, and antiplatelet aggregation inhibitory actions [117]. These polyphenols impeded the metabolism of xenobiotic-metabolizing enzymes, resulting in a shift in the telophase mitotic process and, as a result, cell division disruption [118].

**7.4. Peptides**

Peptides of various types have been detected in a wide spectrum of marine flora. Nearly 2500 novel peptides with anti-proliferative action have been found in the recent decade [119] Cytotoxicity was induced in human HeLa cervical cancer cells by the cyclic depsipeptide apratoxin A, which inhibited cell cycle 35/64. Coibamide A [120], a cyclic depsipeptide isolated from Leptolyngbya sp., and lyngbyabellin B, a cyclic depsipeptide obtained from Lyngbya majuscule, show a similar mechanistic effect. [121]. Peptides produced by Lyngbya spp. and Notoc spp. can inhibit cell growth via microfilament breakdown, secretory route blockage, and other intracellular processes. [122]. Scopulariopsis brevicaulis produces spulularide A and B, two new cyclodepsipeptides that inhibit colon and pancreatic cancer cell proliferation significantly. Sansalvamide A, a cyclic depsipeptide, was synthesised from a variety of marine mushrooms. A mammalian cell line has discovered a connection between a heat shock protein (HSP90) and a cancer protein client, despite the fact that the precise mechanism of this depsipeptide is unknown. Sansalvamide A, an anti-tumor medication, binds to the N-middle domain of HSP90 to stop the formation of protein complexes [81].

**8. Mangroves and other coastal plants**

Mangroves are known to have secondary metabolites that are effective cancer preventives. Although having abundant chemically loaded resources, the mangrove flora has not been extensively researched for anticancer substances [123]. Anticancer medications could be based on seventeen different mangrove species **(Table 2)**. The alkaloid 1.2, dithiolane (Brugin), derived from Bruguiera sexangular sulfide, exhibits anti-Sarcoma-180 and anti-Lewis lung cancer antibodies. Tannins from a similar material have been shown to be anticancer in lung cancer cases [124]. Tetranor triterpenoids (xylogranatins A to D) are poisonous to a variety of deadly tumour cell lines, in contrast to limonoid forms such granaxylocarpins A and B, which are cytotoxic to P-388 leukaemia [125]. Tetranor triterpenoids are anticancer mixtures derived from the mangrove Xylocarpus granatum, popularly known as the cannonball mangrove. A marina is cytotoxic to many cancerous tumour cell lines, including K562 and HeLa. Large cell lines like KB and NCI-H187 respond similarly to compound cardenolide glycoside groups produced from Cerbera odollam seeds, including 2'-O-acetyl cerleaside A, 17b-neriifoline, and cerberin [123].

**Table 2: Some of the anticancer properties of marine floral compounds.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Marine flora** | **Chemical** | **Biological activity** | **Ref.** |
|  |
| **Microbial flora** |
|  |
| Microcystis aeruginosa | Siatoxin, MicroviridinToxin BE-4 | Anticancer, antibiotics | [126,127] |
| Streptomyces peucetius | Daunorubicin | Acute myeloid and acute lymphocytic leukemia anticancer interventions | [128] |
|  |
| **Algal flora** |
|  |
| Cyanobacteria Nostoc linckia and Nostoc spongiaeforme var. tenue | Borophycin | Human colorectal adenocarcinoma activity and cytotoxicity against human epidermoid carcinoma (LoVo) | [129] |
| Cyanobacteria | Apratoxins | The inhibition of certain cancer cell lines | [130] |
| Nostoc linckia | Cyptophycin 1 | Human solid tumors and tumor cell lines: cytotoxicity | [131] |
| Nostoc spongiaeforme | Cryptophycin 8 | Greater in vivo therapeutic effectiveness and less toxicity compared to cryptophycin 14 | [132] |
| Chondria sp. | Condriamide A | Cytotoxicity | [133] |
| Caulerpa sp. | Caulerpenyne | Anticancer, antitumour, anticancer,and antiproliferating activity | [134–136] |
| Cystophora sp. | Meroterpenes and Usneoidone | Antitumour | [137] |
| Symploca sp. | Largazole | Antiproliferative activity | [138] |
| Leptolyngbya sp. | coibamide A | cytotoxicity against mouse neuro-2a and NCIH460 lung cells | [120] |
| Palmaria palmata | Phloroglucinol and its polymers, including deckol, 8,8′-bieckol, dieckol, phlorofucofuroeckol A (a pentamer)  | Phlorotannins' antioxidant action | [139] |
| Sargassum thunbergii | Crude | Inhibition of tumor metastasis and antitumor activity in rat mammary adeno carcinoma cells (13762 MAT) | [140,141] |
| Ascophyllum nodosum | Fucoidan | Antimetastatic, antiproliferative antitumour, fibrinolytic,and anticancer, | [80,142] |
|  |
| Mangroves and other coastal plants |
|  |
| Ceriops decandra | Lignins | Antioxidant | [143] |
| Ceriops decandra | Mangrove tea | Anticancer | [144] |
| Acanthus ilicifolius | Derivatives of benzoxazolineFrom ribose | Anticancer | [145] |

**15. Conclusion and Future perspectives**

Marine creatures have emerged as an intriguing source of both known and unknown substances with the potential to provide long-term economic and human advantages in recent decades. Many of these substances have shown tremendous promise as therapeutics, with specific and robust effects against a variety of disorders, including cancer. The current pipeline has demonstrated its potential as a source of anticancer medicines. Six of the nine drugs now available are used to treat cancer, and other chemicals derived from or produced from marine organisms are currently undergoing clinical studies to see if they may also cure cancer. Yet, compared to the overall number of identified compounds with anticancer potential, the number of substances in use or undergoing clinical studies is small. [146].Many tumor cell lines have been shown to have in vitro anticancer activity, including those derived from cancers of the lung, kidney, prostate, melanoma, bladder, osteosarcoma, breast, and lymphoid .Apoptosis, necrosis, and lysis of tumor cells are thought to be the main pathways through which marine materials inhibit tumor growth both in vitro and in vivo, according to the majority of studies on the topic [147]. Technological advancements and scientific breakthroughs established a foundation for studying a wide range of chemically distinct, physiologically active, and taxonomically diverse marine floras.Successful marine-derived compounds such as trabectedin, eribulin, brentuximab vedotin, and cytarabine have been demonstrated to be extremely beneficial in pre-clinical and clinical research for preventing oxidative DNA damage, inducing apoptosis, decreasing carcinogenesis, and activating macrophages. Lastly, therapy strategies and the current use of marine-derived components are explored, as well as their future direction and clinical trials as anticancer drugs.

**References**

1. Kiuru, P.; Valeria DʼAuria, M.; Muller, C.D.; Tammela, P.; Vuorela, H.; Yli-Kauhaluoma, J. Exploring Marine Resources for Bioactive Compounds. *Planta Medica* 2014, *80*, 1234–1246.

2. Hu, Y.; Chen, J.; Hu, G.; Yu, J.; Zhu, X.; Lin, Y.; Chen, S.; Yuan, J. Statistical Research on the Bioactivity of New Marine Natural Products Discovered during the 28 Years from 1985 to 2012. *Marine Drugs* 2015, *13*, 202–221.

3. Hassan, S.S. ul; Anjum, K.; Abbas, S.Q.; Akhter, N.; Shagufta, B.I.; Shah, S.A.A.; Tasneem, U. Emerging Biopharmaceuticals from Marine Actinobacteria. *Environmental Toxicology and Pharmacology* 2017, *49*, 34–47.

4. Desbois, A.P. How Might We Increase Success in Marine-Based Drug Discovery? *Expert Opinion on Drug Discovery* 2014, *9*, 985–990.

5. Lee, J.Y.; Orlikova, B.; Diederich, M. Signal Transducers and Activators of Transcription (STAT) Regulatory Networks in Marine Organisms: From Physiological Observations towards Marine Drug Discovery. *Marine Drugs* 2015, *13*, 4967–4984.

6. Lee, J.Y.; Orlikova, B.; Diederich, M. Signal Transducers and Activators of Transcription (STAT) Regulatory Networks in Marine Organisms: From Physiological Observations towards Marine Drug Discovery. *Marine Drugs* 2015, *13*, 4967–4984.

7. Ramsay, R.R.; Popovic‐Nikolic, M.R.; Nikolic, K.; Uliassi, E.; Bolognesi, M.L. A Perspective on Multi‐target Drug Discovery and Design for Complex Diseases. *Clinical and Translational Medicine* **2018**, *7*, doi:10.1186/s40169-017-0181-2.

8. Cheng, Y.Y.; Hsieh, C.H.; Tsai, T.H. Concurrent Administration of Anticancer Chemotherapy Drug and Herbal Medicine on the Perspective of Pharmacokinetics. *Journal of Food and Drug Analysis* 2018, *26*, S88–S95.

9. Ang, K.K.H.; Holmes, M.J.; Higa, T.; Hamann, M.T.; Kara, U.A.K. In Vivo Antimalarial Activity of the Beta-Carboline Alkaloid Manzamine A. *Antimicrobial Agents and Chemotherapy* **2000**, *44*, 1645–1649.

10. Ang, K.; Holmes, M.; Kara, U. Immune-Mediated Parasite Clearance in Mice Infected with Plasmodium Berghei Following Treatment with Manzamine A. *Parasitology Research* **2001**, *87*, 715–721.

11. Bellier, J.; Nokin, M.J.; Lardé, E.; Karoyan, P.; Peulen, O.; Castronovo, V.; Bellahcène, A. Methylglyoxal, a Potent Inducer of AGEs, Connects between Diabetes and Cancer. *Diabetes Research and Clinical Practice* 2019, *148*, 200–211.

12. Cárceles, C.M.; Fernández-Varón, E.; Marín, P.; Escudero, E. Tissue Disposition of Azithromycin after Intravenous and Intramuscular Administration to Rabbits. *Veterinary Journal* **2007**, *174*, 154–159, doi:10.1016/j.tvjl.2006.05.022.

13. Sawadogo, W.R.; Boly, R.; Cerella, C.; Teiten, M.H.; Dicato, M.; Diederich, M. A Survey of Marine Natural Compounds and Their Derivatives with Anti-Cancer Activity Reported in 2012. *Molecules* 2015, *20*, 7097–7142.

14. Sawadogo, W.R.; Boly, R.; Cerella, C.; Teiten, M.H.; Dicato, M.; Diederich, M. A Survey of Marine Natural Compounds and Their Derivatives with Anti-Cancer Activity Reported in 2012. *Molecules* 2015, *20*, 7097–7142.

15. Li, G.; Lou, H.X. Strategies to Diversify Natural Products for Drug Discovery. *Medicinal Research Reviews* **2018**, *38*, 1255–1294, doi:10.1002/MED.21474.

16. Newman, D.J.; Cragg, G.M.; Snader, K.M. Natural Products as Sources of New Drugs over the Period 1981-2002. *Journal of Natural Products* 2003, *66*, 1022–1037.

17. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs over the 30 Years from 1981 to 2010. *Journal of Natural Products* 2012, *75*, 311–335.

18. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs from 1981 to 2014. *Journal of Natural Products* **2016**, *79*, 629–661, doi:10.1021/ACS.JNATPROD.5B01055/SUPPL\_FILE/NP5B01055\_SI\_002.DOCX.

19. White, J. Drug Addiction: From Basic Research to Therapy. *Drug and Alcohol Review* **2009**, *28*, 455–455, doi:10.1111/j.1465-3362.2009.00088\_1.x.

20. Nobili, S.; Lippi, D.; Witort, E.; Donnini, M.; Bausi, L.; Mini, E.; Capaccioli, S. *Natural Compounds for Cancer Treatment and Prevention*; Academic Press, 2009; Vol. 59, pp. 365–378;.

21. Newman, D.J.; Cragg, G.M. Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. *Marine Drugs* 2014, *12*, 255–278.

22. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs over the 30 Years from 1981 to 2010. *Journal of Natural Products* 2012, *75*, 311–335.

23. Althagbi, H.I.; Alarif, W.M.; Al-Footy, K.O.; Abdel-Lateff, A. Marine-Derived Macrocyclic Alkaloids (MDMAs): Chemical and Biological Diversity. *Marine Drugs* 2020, *18*.

24. Newman, D.J.; Cragg, G.M. Drugs and Drug Candidates from Marine Sources: An Assessment of the Current “State of Play.” *Planta Medica* 2016, *82*, 775–789.

25. Sea, D.M.-D. from the; 2000, undefined Aquacultural Production of Bryostatin 1 and Ecteinascidin 743. *books.google.com*.

26. Dhorajiya, B.; Malani, M.; Dholakiya, B. Extraction and Preservation Protocol of Anti-Cancer Agents from Marine World. *Section Title: Pharmaceuticals* **2011**, *2012*, No pp. given.

27. Hu, G.P.; Yuan, J.; Sun, L.; She, Z.G.; Wu, J.H.; Lan, X.J.; Zhu, X.; Lin, Y.C.; Chen, S.P. Statistical Research on Marine Natural Products Based on Data Obtained between 1985 and 2008. *Marine Drugs 2011, Vol. 9, Pages 514-525* **2011**, *9*, 514–525, doi:10.3390/MD9040514.

28. Ruiz-Torres, V.; Encinar, J.A.; Herranz-López, M.; Pérez-Sánchez, A.; Galiano, V.; Barrajón-Catalán, E.; Micol, V. An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs. *Molecules* **2017**, *22*, doi:10.3390/molecules22071037.

29. Saeed, A.F.U.H.; Su, J.; Ouyang, S. Marine-Derived Drugs: Recent Advances in Cancer Therapy and Immune Signaling. *Biomedicine and Pharmacotherapy* 2021, *134*.

30. Greenwell, M.; Rahman, P.K.S.M. Medicinal Plants: Their Use in Anticancer Treatment. *International journal of pharmaceutical sciences and research* **2015**, *6*, 4103, doi:10.13040/IJPSR.0975-8232.6(10).4103-12.

31. Langseth, L. *Oxidants, Antioxidants, and Disease Prevention*; 1995; ISBN 0944398529.

32. Hamidi, M.; Safarzadeh Kozani, P.; Safarzadeh Kozani, P.; Pierre, G.; Michaud, P.; Delattre, C. Marine Bacteria versus Microalgae: Who Is the Best for Biotechnological Production of Bioactive Compounds with Antioxidant Properties and Other Biological Applications? *Marine Drugs 2020, Vol. 18, Page 28* **2019**, *18*, 28, doi:10.3390/MD18010028.

33. Finkel, T. Signal Transduction by Reactive Oxygen Species. *Journal of Cell Biology* **2011**, *194*, 7–15, doi:10.1083/JCB.201102095.

34. Santos-Buelga, C.; González-Paramás, A.M.; Oludemi, T.; Ayuda-Durán, B.; González-Manzano, S. Plant Phenolics as Functional Food Ingredients. In *Advances in Food and Nutrition Research*; 2019; Vol. 90, pp. 183–257 ISBN 9780128165676.

35. Sedlak, T.W.; Paul, B.D.; Parker, G.M.; Hester, L.D.; Snowman, A.M.; Taniguchi, Y.; Kamiya, A.; Snyder, S.H.; Sawa, A. The Glutathione Cycle Shapes Synaptic Glutamate Activity. *Proceedings of the National Academy of Sciences of the United States of America* **2019**, *116*, 2701–2706, doi:10.1073/pnas.1817885116.

36. Meister, A. Glutathione Metabolism and Its Selective Modification. *Journal of Biological Chemistry* 1988, *263*, 17205–17208.

37. MacKay, D.; Andrea Wong, N.; Nguyen, H. Vitamin and Mineral Safety 3 Rd Edition. **2014**.

38. Council; For; Responsible; Nutrition *Niacin: Nicotinic Acid, Nicotinamide, and Inositol Hexanicotinate. Vitamin and Mineral Safety 3 Rd Edition (2013) Council for Responsible Nutrition (CRN) Www.Crnusa.Org*; 2013;

39. Kuleta, P.; Lasham, J.; Sarewicz, M.; Ekiert, I.; Sharma, V.; Ekiert, R.; Osyczka, A. Hydrogen Bonding Rearrangement by a Mitochondrial Disease Mutation in Cytochrome Bc1 Perturbs Heme BH Redox Potential and Spin State. *Proceedings of the National Academy of Sciences of the United States of America* **2021**, *118*, doi:10.1073/pnas.2026169118.

40. Weber, P.; Bendich, A.; Schalch, W. Vitamin C and Human Health - A Review of Recent Data Relevant to Human Requirements. *International Journal for Vitamin and Nutrition Research* **1996**, *66*, 19–30.

41. Tannenbaum, S.R.; Wishnok, J.S.; Leaf, C.D. Inhibition of Nitrosamine Formation by Ascorbic Acid. In Proceedings of the American Journal of Clinical Nutrition; 1991; Vol. 53.

42. Reang, J.; Sharma, P.C.; Thakur, V.K.; Majeed, J. Understanding the Therapeutic Potential of Ascorbic Acid in the Battle to Overcome Cancer. *Biomolecules* 2021, *11*.

43. Sharma, G.N.; Gupta, G.; Sharma, P. A Comprehensive Review of Free Radicals, Antioxidants, and Their Relationship with Human Ailments. *Critical Reviews in Eukaryotic Gene Expression* 2018, *28*, 139–154.

44. Barreca, M.; Spanò, V.; Montalbano, A.; Cueto, M.; Díaz Marrero, A.R.; Deniz, I.; Erdoğan, A.; Bilela, L.L.; Moulin, C.; Taffin-De-Givenchy, E.; et al. Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. *Marine Drugs* 2020, *18*, 619.

45. Sardas, S. The Role of Antioxidants in Cancer Prevention and Treatment. *http://dx.doi.org/10.1177/1420326X03039009* **2003**, *12*, 401–404, doi:10.1177/1420326X03039009.

46. Waldmann, T.A. Effective Cancer Therapy Through Immunomodulation\*. *https://doi.org/10.1146/annurev.med.56.082103.104549* **2006**, *57*, 65–81, doi:10.1146/ANNUREV.MED.56.082103.104549.

47. Carneiro, B.A.; El-Deiry, W.S. Targeting Apoptosis in Cancer Therapy. *Nature Reviews Clinical Oncology* 2020, *17*, 395–417.

48. Warren, C.F.A.; Wong-Brown, M.W.; Bowden, N.A. BCL-2 Family Isoforms in Apoptosis and Cancer. *Cell Death and Disease* 2019, *10*.

49. Lossi, L.; Castagna, C.; Merighi, A. Caspase-3 Mediated Cell Death in the Normal Development of the Mammalian Cerebellum. *International Journal of Molecular Sciences* 2018, *19*.

50. Woynarowska, B.A.; Roberts, K.; Woynarowski, J.M.; MacDonald, J.R.; Herman, T.S. Targeting Apoptosis by Hydroxymethylacylfulvene in Combination with Gamma Radiation in Prostate Tumor Cells. *Radiation Research* **2000**, *154*, 429–438, doi:10.1667/0033-7587(2000)154[0429:TABHIC]2.0.CO;2.

51. Zhang, W.; Couldwell, W.T.; Song, H.; Takano, T.; Lin, J.H.C.; Nedergaard, M. Tamoxifen-Induced Enhancement of Calcium Signaling in Glioma and MCF-7 Breast Cancer Cells. *Cancer Research* **2000**, *60*, 5395–5400.

52. Marrero, A.D.; Quesada, A.R.; Martínez-Poveda, B.; Medina, M.Á. Antiangiogenic Phytochemicals Constituent of Diet as Promising Candidates for Chemoprevention of Cancer. *Antioxidants* **2022**, *11*, 302, doi:10.3390/antiox11020302.

53. Zhai, K.; Brockmüller, A.; Kubatka, P.; Shakibaei, M.; Büsselberg, D. Curcumin’s Beneficial Effects on Neuroblastoma: Mechanisms, Challenges, and Potential Solutions. *Biomolecules* 2020, *10*, 1–28.

54. Hwang, J.; Yadav, D.; Lee, P.C.W.; Jin, J.O. Immunomodulatory Effects of Polysaccharides from Marine Algae for Treating Cancer, Infectious Disease, and Inflammation. *Phytotherapy Research* **2021**, doi:10.1002/ptr.7348.

55. Dowlath, M.J.H.; Karuppannan, S.K.; Sinha, P.; Dowlath, N.S.; Arunachalam, K.D.; Ravindran, B.; Chang, S.W.; Nguyen-Tri, P.; Nguyen, D.D. Effects of Radiation and Role of Plants in Radioprotection: A Critical Review. *Science of the Total Environment* 2021, *779*.

56. Wang, W.; Xue, C.; Mao, X. Radioprotective Effects and Mechanisms of Animal, Plant and Microbial Polysaccharides. *International Journal of Biological Macromolecules* 2020, *153*, 373–384.

57. Tomori, M.; Nagamine, T.; Miyamoto, T.; Iha, M. Evaluation of the Immunomodulatory Effects of Fucoidan Derived from Cladosiphon Okamuranus Tokida in Mice. *Marine Drugs* **2019**, *17*, doi:10.3390/md17100547.

58. Chen, B.R.; Hsu, K.T.; Li, T.L.; Chan, Y.L.; Wu, C.J. Topical Application of Fucoidan Derived from Cladosiphon Okamuranus Alleviates Atopic Dermatitis Symptoms through Immunomodulation. *International Immunopharmacology* **2021**, *101*, doi:10.1016/j.intimp.2021.108362.

59. Park, H. Bin; Hwang, J.; Lim, S.M.; Zhang, W.; Jin, J.O. Dendritic Cell-Mediated Cancer Immunotherapy with Ecklonia Cava Fucoidan. *International Journal of Biological Macromolecules* **2020**, *159*, 941–947, doi:10.1016/j.ijbiomac.2020.05.160.

60. Xu, B.; Cui, Y.; Wang, W.; Li, S.; Lyu, C.; Wang, S.; Bao, W.; Wang, H.; Qin, M.; Liu, Z.; et al. Immunomodulation-Enhanced Nanozyme-Based Tumor Catalytic Therapy. *Advanced Materials* **2020**, *32*, 2003563, doi:10.1002/ADMA.202003563.

61. advances, R.C.-B.; 2002, undefined Fulfilling the Promise of Biotechnology. *Elsevier*.

62. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. *Choice Reviews Online* **2008**, *45*, 45-5024-45–5024, doi:10.5860/choice.45-5024.

63. Singh, S.; Tiwari, D.; Gautam, S.S.; Singh, M.K.; Pal, S.K. Seaweed: An Alternative Liquid Fertilizer for Plant Growth. *International Journal of Current Microbiology and Applied Sciences* **2019**, *8*, 772–781, doi:10.20546/ijcmas.2019.812.101.

64. Sithranga Boopathy, N.; Kathiresan, K. Anticancer Drugs from Marine Flora: An Overview. *Journal of Oncology* **2010**, doi:10.1155/2010/214186.

65. Lordan, S.; Ross, R.P.; Stanton, C. Marine Bioactives as Functional Food Ingredients: Potential to Reduce the Incidence of Chronic Diseases. *Marine Drugs 2011, Vol. 9, Pages 1056-1100* **2011**, *9*, 1056–1100, doi:10.3390/MD9061056.

66. Janakiram, N.B.; Mohammed, A.; Rao, C. V. Sea Cucumbers Metabolites as Potent Anti-Cancer Agents. *Marine Drugs 2015, Vol. 13, Pages 2909-2923* **2015**, *13*, 2909–2923, doi:10.3390/MD13052909.

67. Demain, A.L.; Vaishnav, P. Natural Products for Cancer Chemotherapy. *Microbial Biotechnology* **2011**, *4*, 687–699, doi:10.1111/J.1751-7915.2010.00221.X.

68. Dyshlovoy, S.A.; Honecker, F. Marine Compounds and Cancer: 2017 Updates. *Marine Drugs* 2018, *16*, 41.

69. Jimenez, P.C.; Wilke, D. V; Branco, P.C.; Bauermeister, A.; Rezende-Teixeira, P.; Gaudêncio, S.P.; Costa-Lotufo, L. V. Enriching Cancer Pharmacology with Drugs of Marine Origin. *British Journal of Pharmacology* 2020, *177*, 3–27.

70. Sharifi-Rad, J.; Quispe, C.; Patra, J.K.; Singh, Y.D.; Panda, M.K.; Das, G.; Adetunji, C.O.; Michael, O.S.; Sytar, O.; Polito, L.; et al. Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy. *Oxidative Medicine and Cellular Longevity* 2021, *2021*.

71. Hong, P.; Liu, Q.W.; Xie, Y.; Zhang, Q.H.; Liao, L.; He, Q.Y.; Li, B.; Xu, W.W. Echinatin Suppresses Esophageal Cancer Tumor Growth and Invasion through Inducing AKT/MTOR-Dependent Autophagy and Apoptosis. *Cell Death and Disease* **2020**, *11*, doi:10.1038/s41419-020-2730-7.

72. Majolo, F.; de Oliveira Becker Delwing, L.K.; Marmitt, D.J.; Bustamante-Filho, I.C.; Goettert, M.I. Medicinal Plants and Bioactive Natural Compounds for Cancer Treatment: Important Advances for Drug Discovery. *Phytochemistry Letters* **2019**, *31*, 196–207, doi:10.1016/j.phytol.2019.04.003.

73. Yousaf, M.; Hammond, N.L.; Peng, J.; Wahyuono, S.; McIntosh, K.A.; Charman, W.N.; Mayer, A.M.S.; Hamann, M.T. New Manzamine Alkaloids from an Indo-Pacific Sponge. Pharmacokinetics, Oral Availability, and the Significant Activity of Several Manzamines against HIV-I, AIDS Opportunistic Infections, and Inflammatory Diseases. *Journal of Medicinal Chemistry* **2004**, *47*, 3512–3517, doi:10.1021/jm030475b.

74. Deng, S.; Shanmugam, M.K.; Kumar, A.P.; Yap, C.T.; Sethi, G.; Bishayee, A. Targeting Autophagy Using Natural Compounds for Cancer Prevention and Therapy. *Cancer* 2019, *125*, 1228–1246.

75. Choudhary, A.; Naughton, L.M.; Montánchez, I.; Dobson, A.D.W.; Rai, D.K. Current Status and Future Prospects of Marine Natural Products (MNPs) as Antimicrobials. *Marine Drugs* 2017, *15*.

76. Pereira, F.; Aires-de-Sousa, J. Computational Methodologies in the Exploration of Marine Natural Product Leads. *Marine Drugs* 2018, *16*.

77. Khalifa, S.A.M.; Elias, N.; Farag, M.A.; Chen, L.; Saeed, A.; Hegazy, M.E.F.; Moustafa, M.S.; El-Wahed, A.A.; Al-Mousawi, S.M.; Musharraf, S.G.; et al. Marine Natural Products: A Source of Novel Anticancer Drugs. *Marine Drugs* 2019, *17*, 491.

78. Slichenmyer, W.J.; Von Hoff, D.D. New Natural Products in Cancer Chemotherapy. *The Journal of Clinical Pharmacology* **1990**, *30*, 770–788, doi:10.1002/J.1552-4604.1990.TB01873.X.

79. Wang, H.-Y.; Oltion, K.; Al-Khdhairawi, A.A.Q.; Weber, J.-F.F.; Taunton, J. Total Synthesis and Biological Characterization of SR-A3, a Ternatin-Related EEF1A Inhibitor with Enhanced Cellular Residence Time. *bioRxiv* **2020**, 2020.10.06.325498, doi:10.1101/2020.10.06.325498.

80. Vischer, P.; Buddecke, E. Different Action of Heparin and Fucoidan on Arterial Smooth Muscle Cell Proliferation and Thrombospondin and Fibronectin Metabolism. *European Journal of Cell Biology* **1991**, *56*, 407–414.

81. Vasko, R.C.; Rodriguez, R.A.; Cunningham, C.N.; Ardi, V.C.; Agard, D.A.; McAlpine, S.R. Mechanistic Studies of Sansalvamide A-Amide: An Allosteric Modulator of Hsp90. *ACS Medicinal Chemistry Letters* **2010**, *1*, 4–8, doi:10.1021/ML900003T/SUPPL\_FILE/ML900003T\_SI\_001.PDF.

82. Devi, S.K.; Velmurugan, D. MOLECULAR MODELING, QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP AND PHARMACOPHORE STUDIES ON ANTIVIRAL, ANTIMALARIAL AND ANTIINFLAMMATORY BIOACTIVE COMPOUNDS FROM MARINE SOURCES. **2015**, *8*.

83. Lopes-Costa, E.; Abreu, M.; Gargiulo, D.; Rocha, E.; Ramos, A.A. Anticancer Effects of Seaweed Compounds Fucoxanthin and Phloroglucinol, Alone and in Combination with 5-Fluorouracil in Colon Cells. *https://doi.org/10.1080/15287394.2017.1357297* **2017**, *80*, 776–787, doi:10.1080/15287394.2017.1357297.

84. Aguilar-Briseño, J.A.; Cruz-Suarez, L.E.; Sassi, J.F.; Ricque-Marie, D.; Zapata-Benavides, P.; Mendoza-Gamboa, E.; Rodríguez-Padilla, C.; Trejo-Avila, L.M. Sulphated Polysaccharides from Ulva Clathrata and Cladosiphon Okamuranus Seaweeds Both Inhibit Viral Attachment/Entry and Cell-Cell Fusion, in NDV Infection. *Marine Drugs* **2015**, *13*, 697–712, doi:10.3390/md13020697.

85. Suarez-Jimenez, G.M.; Burgos-Hernandez, A.; Ezquerra-Brauer, J.M. Bioactive Peptides and Depsipeptides with Anticancer Potential: Sources from Marine Animals. *Marine Drugs 2012, Vol. 10, Pages 963-986* **2012**, *10*, 963–986, doi:10.3390/MD10050963.

86. Deng, L.; Meng, T.; Chen, L.; Wei, W.; Wang, P. The Role of Ubiquitination in Tumorigenesis and Targeted Drug Discovery. *Signal Transduction and Targeted Therapy* 2020, *5*.

87. Khalid, A.F. Bin; Tan, J.J.; Yong, Y.K. Malaysian Tualang Honey and Its Potential Anti-Cancer Properties: A Review. *Sains Malaysiana* **2018**, *47*, 2705–2711, doi:10.17576/jsm-2018-4711-14.

88. Lu, J.; Ma, Y.; Liang, J.; Xing, Y.; Xi, T.; Lu, Y. Aureolic Acids from a Marine-Derived Streptomyces Sp. WBF16. *Microbiological Research* **2012**, *167*, 590–595, doi:10.1016/j.micres.2012.06.001.

89. Zhang, X.; Ye, X.; Chai, W.; Lian, X.Y.; Zhang, Z. New Metabolites and Bioactive Actinomycins from Marine-Derived Streptomyces Sp. ZZ338. *Marine Drugs* **2016**, *14*, doi:10.3390/md14100181.

90. Li, Z.Y.; Xu, G. Sen; Li, X. A Unique Topoisomerase Ii Inhibitor with Dose-Affected Anticancer Mechanisms and Less Cardiotoxicity. *Cells* **2021**, *10*, doi:10.3390/cells10113138.

91. Yazdiniapour, Z.; Mirian, M.; Zolfaghari, B.; Fitoterapia, P.M.-; 2022, U. Myrsinane-Type Diterpenes from Euphorbia Gedrosiaca with Cell Growth Inhibitory Activity and Apoptotic Effects on Melanoma Cancer Cells. *fitoterapia* **2022**, 105138.

92. Visone, V.; Szabó, I.; Perugino, G.; Hudecz, F.; Bánóczi, Z.; Valenti, A. Topoisomerases Inhibition and DNA Binding Mode of Daunomycin–Oligoarginine Conjugate. *Journal of Enzyme Inhibition and Medicinal Chemistry* **2020**, *35*, 1363–1371, doi:10.1080/14756366.2020.1780226.

93. Tewari, D.; Patni, P.; Bishayee, A.; Sah, A.N.; Bishayee, A. Natural Products Targeting the PI3K-Akt-MTOR Signaling Pathway in Cancer: A Novel Therapeutic Strategy. *Seminars in Cancer Biology* 2019.

94. Monk, B.J.; Herzog, T.J.; Kaye, S.B.; Krasner, C.N.; Vermorken, J.B.; Muggia, F.M.; Pujade-Lauraine, E.; Lisyanskaya, A.S.; Makhson, A.N.; Rolski, J.; et al. Trabectedin plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. *Journal of Clinical Oncology* **2010**, *28*, 3107–3114, doi:10.1200/JCO.2009.25.4037.

95. Assi, T.; Kattan, J.; El Rassy, E.; Honore, C.; Dumont, S.; Mir, O.; Le Cesne, A. A Comprehensive Review of the Current Evidence for Trabectedin in Advanced Myxoid Liposarcoma. *Cancer Treatment Reviews* 2019, *72*, 37–44.

96. Blanco, F.A.; Czikora, A.; Kedei, N.; You, Y.; Mitchell, G.A.; Pany, S.; Ghosh, A.; Blumberg, P.M.; Das, J. Munc13 Is a Molecular Target of Bryostatin 1. *Biochemistry* **2019**, *58*, 3016–3030, doi:10.1021/acs.biochem.9b00427.

97. Miri, M.R.; Zare, A.; Saberzadeh, J.; Baghban, N.; Nabipour, I.; Tamadon, A. Anti-Lung Cancer Marine Compounds: A Review. *Therapeutic Innovation and Regulatory Science* 2022, *56*, 191–205.

98. Wall, N.R.; Mohammad, R.M.; Reddy, K.B.; Al-Katib, A.M. Bryostatin 1 Induces Ubiquitination and Proteasome Degradation of Bcl-2 in the Human Acute Lymphoblastic Leukemia Cell Line, Reh. *International journal of molecular medicine* **2000**, *5*, 165–171, doi:10.3892/ijmm.5.2.165.

99. Deng, S.; Shanmugam, M.K.; Kumar, A.P.; Yap, C.T.; Sethi, G.; Bishayee, A. Targeting Autophagy Using Natural Compounds for Cancer Prevention and Therapy. *Cancer* 2019, *125*, 1228–1246.

100. Singh, R.; Sharma, M.; Joshi, P.; Rawat, D. Clinical Status of Anti-Cancer Agents Derived from Marine Sources. *Anti-Cancer Agents in Medicinal Chemistry* **2013**, *8*, 603–617, doi:10.2174/187152008785133074.

101. Fenical, W. (Bill) Marine Microbial Natural Products: The Evolution of a New Field of Science. *Journal of Antibiotics* 2020, *73*, 481–487.

102. Fenical, W. (Bill) Marine Microbial Natural Products: The Evolution of a New Field of Science. *Journal of Antibiotics* 2020, *73*, 481–487.

103. Bhatnagar, I.; Kim, S.K. Immense Essence of Excellence: Marine Microbial Bioactive Compounds. *Marine Drugs* 2010, *8*, 2673–2701.

104. Schwartsmann, G.; Da Rocha, A.B.; Berlinck, R.G.S.; Jimeno, J. *Marine Organisms as a Source of New Anticancer Agents*; Elsevier, 2001; Vol. 2, pp. 221–225;.

105. Karthikeyan, A.; Joseph, A.; Nair, B.G. Promising Bioactive Compounds from the Marine Environment and Their Potential Effects on Various Diseases. *Journal of Genetic Engineering and Biotechnology 2022 20:1* **2022**, *20*, 1–38, doi:10.1186/S43141-021-00290-4.

106. Mizrahy, S.; Peer, D. Polysaccharides as Building Blocks for Nanotherapeutics. *Chemical Society Reviews* **2012**, *41*, 2623–2640, doi:10.1039/C1CS15239D.

107. Gorelik, E. Augmentation of the Antimetastatic Effect of Anticoagulant Drugs by Immunostimulation in Mice. *Cancer Research* **1987**, *47*, 809–815.

108. Dziarski, R. Enhancement of Mixed Leukocyte Reaction and Cytotoxic Antitumor Responses by Heparin. *The Journal of Immunology* **1989**, *143*, 356–365.

109. Joyce, J.A.; Freeman, C.; Meyer-Morse, N.; Parish, C.R.; Hanahan, D. A Functional Heparan Sulfate Mimetic Implicates Both Heparanase and Heparan Sulfate in Tumor Angiogenesis and Invasion in a Mouse Model of Multistage Cancer. *Oncogene* **2005**, *24*, 4037–4051, doi:10.1038/sj.onc.1208602.

110. Berry, D.; Lynn, D.M.; Sasisekharan, R.; Langer, R. Poly(β-Amino Ester)s Promote Cellular Uptake of Heparin and Cancer Cell Death. *Chemistry and Biology* **2004**, *11*, 487–498, doi:10.1016/j.chembiol.2004.03.023.

111. Itoh, H.; Noda, H.; Amano, H.; Ito, H. Immunological Analysis of Inhibition of Lung Metastases by Fucoidan (GIV-A) Prepared from Brown Seaweed Sargassum Thunbergii. *Anticancer Research* **1995**, *15*, 1937–1947.

112. Boisson-Vidal, C.; Zemani, F.; Caligiuri, G.; Galy-Fauroux, I.; Colliec-Jouault, S.; Helley, D.; Fischer, A.-M. Neoangiogenesis Induced by Progenitor Endothelial Cells: Effect of Fucoidan from Marine Algae. *Cardiovascular & Hematological Agents in Medicinal Chemistry* **2012**, *5*, 67–77, doi:10.2174/187152507779315778.

113. Aisa, Y.; Miyakawa, Y.; Nakazato, T.; Shibata, H.; Saito, K.; Ikeda, Y.; Kizaki, M. Fucoidan Induces Apoptosis of Human HS-Sultan Cells Accompanied by Activation of Caspase-3 and down-Regulation of ERK Pathways. *American Journal of Hematology* **2005**, *78*, 7–14, doi:10.1002/ajh.20182.

114. Senni, K.; Pereira, J.; Gueniche, F.; Delbarre-Ladrat, C.; Sinquin, C.; Ratiskol, J.; Godeau, G.; Fischer, A.M.; Helley, D.; Colliec-Jouault, S. Marine Polysaccharides: A Source of Bioactive Molecules for Cell Therapy and Tissue Engineering. *Marine Drugs 2011, Vol. 9, Pages 1664-1681* **2011**, *9*, 1664–1681, doi:10.3390/MD9091664.

115. Gross, H.; Goeger, D.E.; Hills, P.; Mooberry, S.L.; Ballantine, D.L.; Murray, T.F.; Valeriote, F.A.; Gerwick, W.H. Lophocladines, Bioactive Alkaloids from the Red Alga Lophocladia Sp. *Journal of Natural Products* **2006**, *69*, 640–644, doi:10.1021/np050519e.

116. Bandaranayake, W.M. Bioactivities, Bioactive Compounds and Chemical Constituents of Mangrove Plants. *Wetlands Ecology and Management* 2002, *10*, 421–452.

117. Yuan, Y. V.; Carrington, M.F.; Walsh, N.A. Extracts from Dulse (Palmaria Palmata) Are Effective Antioxidants and Inhibitors of Cell Proliferation in Vitro. *Food and Chemical Toxicology* **2005**, *43*, 1073–1081, doi:10.1016/j.fct.2005.02.012.

118. Gawron, A.; Kruk, I. Cytotoxic Effect of Xanthotoxol (8-Hydroxypsoralen) on TCTC Cells in Vitro. *Polish Journal of Pharmacology and Pharmacy* **1992**, *44*, 51–57.

119. Malaker, A.; Adil, S.; Ahmad, I.; Engineering, G.; Science, M.B. Therapeutic Potency of Anticancer Peptides. *Journal Of Engineering And Applied Sciences* **2013**, *2*, 82–94.

120. Medina, R.A.; Goeger, D.E.; Hills, P.; Mooberry, S.L.; Huang, N.; Romero, L.I.; Ortega-Barría, E.; Gerwick, W.H.; McPhail, K.L. Coibamide A, a Potent Antiproliferative Cyclic Depsipeptide from the Panamanian Marine Cyanobacterium Leptolyngbya Sp. *Journal of the American Chemical Society* **2008**, *130*, 6324–6325.

121. Kalemkerian, G.P.; Ou, X.; Adil, M.R.; Rosati, R.; Khoulani, M.M.; Madan, S.K.; Pettit, G.R. Activity of Dolastatin 10 against Small-Cell Lung Cancer in Vitro and in Vivo: Induction of Apoptosis and Bcl-2 Modification. *Cancer Chemotherapy and Pharmacology* **1999**, *43*, 507–515, doi:10.1007/s002800050931.

122. Costa, M.; Costa-Rodrigues, J.; Fernandes, M.H.; Barros, P.; Vasconcelos, V.; Martins, R. Marine Cyanobacteria Compounds with Anticancer Properties: A Review on the Implication of Apoptosis. *Marine Drugs* 2012, *10*, 2181–2207.

123. Das, G.; Gouda, S.; Mohanta, Y.K.; Patra, J.K. Mangrove Plants: A Potential Source for Anticancer Drugs. **2015**, *44*, 666–672.

124. Yin, S.; Fan, C.Q.; Wang, X.N.; Lin, L.P.; Ding, J.; Yue, J.M. Xylogranatins A-D: Novel Tetranortriterpenoids with an Unusual 9, 10-Seco Scaffold from Marine Mangrove Xylocarpus Granatum. *Organic Letters* **2006**, *8*, 4935–4938, doi:10.1021/ol062101t.

125. Yin, S.; Fan, C.Q.; Wang, X.N.; Lin, L.P.; Ding, J.; Yue, J.M. Xylogranatins A-D: Novel Tetranortriterpenoids with an Unusual 9, 10-Seco Scaffold from Marine Mangrove Xylocarpus Granatum. *Organic Letters* **2006**, *8*, 4935–4938, doi:10.1021/ol062101t.

126. Arment, A.R.; Carmichael, W.W. EVIDENCE THAT MICROCYSTIN IS A THIO-TEMPLATE PRODUCT1. *Journal of Phycology* **1996**, *32*, 591–597, doi:10.1111/J.0022-3646.1996.00591.X.

127. Shi, L.; Carmichael, W.W.; Kennelly, P.J. Cyanobacterial PPP Family Protein Phosphatases Possess Multifunctional Capabilities and Are Resistant to Microcystin-LR. *Journal of Biological Chemistry* **1999**, *274*, 10039–10046, doi:10.1074/jbc.274.15.10039.

128. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. *Pharmacological Reviews* **2004**, *56*, 185–229, doi:10.1124/PR.56.2.6.

129. Banker, R.; Carmeli, S. Tenuecyclamides A−D, Cyclic Hexapeptides from the Cyanobacterium Nostoc Spongiaeforme Var. Tenue. *Journal of Natural Products* **1998**, *61*, 1248–1251, doi:10.1021/NP980138J.

130. Luesch, H.; Moore, R.E.; Paul, V.J.; Mooberry, S.L.; Corbett, T.H. Isolation of Dolastatin 10 from the Marine Cyanobacterium Symploca Species VP642 and Total Stereochemistry and Biological Evaluation of Its Analogue Symplostatin 1. *Journal of Natural Products* **2001**, *64*, 907–910, doi:10.1021/np010049y.

131. Moore, R.E. Cyclic Peptides and Depsipeptides from Cyanobacteria: A Review. *Journal of Industrial Microbiology* **1996**, *16*, 134–143, doi:10.1007/BF01570074/METRICS.

132. Carmichael, W.W. Cyanobacteria Secondary Metabolites—the Cyanotoxins. *Journal of Applied Bacteriology* **1992**, *72*, 445–459, doi:10.1111/J.1365-2672.1992.TB01858.X.

133. Palermo, J.A.; Flower, P.B.; Seldes, A.M. Chondriamides A and B, New Indolic Metabolites from the Red Alga Chondria Sp. *Tetrahedron Letters* **1992**, *33*, 3097–3100, doi:10.1016/S0040-4039(00)79823-6.

134. Fischel, J.L.; Lemee, R.; Formento, P.; Caldani, C.; Moll, J.L.; Pesando, D.; Meinesz, A.; Grelier, P.; Pietra, F.; Guerriero, A.; et al. Cell Growth Inhibitory Effects of Caulerpenyne, a Sesquiterpenoid from the Marine Algae Caulerpa Taxifolia. *Anticancer Research* **1995**, *15*, 2155–2160.

135. ParentMassin, D.; Fournier, V.; Amade, P.; Lemée, R.; Durand-Clément, M.; Delescluse, C.; Pesando, D. EVALUATION OF THE TOXICOLOGICAL RISK TO HUMANS OF CAULERPENYNE USING HUMAN HEMATOPOIETIC PROGENITORS, MELANOCYTES, AND KERATINOCYTES IN CULTURE. *http://dx.doi.org/10.1080/009841096161924* **2010**, *47*, 47–59, doi:10.1080/009841096161924.

136. Barbier, P.; Guise, S.; Huitorel, P.; Amade, P.; Pesando, D.; Briand, C.; Peyrot, V. Caulerpenyne from Caulerpa Taxifolia Has an Antiproliferative Activity on Tumor Cell Line SK-N-SH and Modifies the Microtubule Network. *Life Sciences* **2001**, *70*, 415–429, doi:10.1016/S0024-3205(01)01396-0.

137. Urones, J.G.; Araujo, M.E.M.; Brito Palma, F.M.S.; Basabe, P.; Marcos, I.S.; Moro, R.F.; Lithgow, A.M.; Pineda, J. Meroterpenes from Cystoseira Usneoides II. *Phytochemistry* **1992**, *31*, 2105–2109, doi:10.1016/0031-9422(92)80372-L.

138. Taori, K.; Paul, V.J.; Luesch, H. Structure and Activity of Largazole, a Potent Antiproliferative Agent from the Floridian Marine Cyanobacterium Symploca Sp. *Journal of the American Chemical Society* **2008**, *130*, 1806–1807, doi:10.1021/ja7110064.

139. Yuan, Y. V.; Carrington, M.F.; Walsh, N.A. Extracts from Dulse (Palmaria Palmata) Are Effective Antioxidants and Inhibitors of Cell Proliferation in Vitro. *Food and Chemical Toxicology* **2005**, *43*, 1073–1081, doi:10.1016/j.fct.2005.02.012.

140. Zhuang, C.; Itoh, H.; Mizuno, T.; Ito, H. Antitumor Active Fucoidan from the Brown Seaweed, Umitoranoo (Sargassum Thunbergii). *Bioscience, Biotechnology, and Biochemistry* **1995**, *59*, 563–567, doi:10.1271/BBB.59.563.

141. Coombe, D.R.; Parish, C.R.; Ramshaw, I.A.; Snowden, J.M. Analysis of the Inhibition of Tumour Metastasis by Sulphated Polysaccharides. *International Journal of Cancer* **1987**, *39*, 82–88, doi:10.1002/IJC.2910390115.

142. Religa, P.; Kazi, M.; Thyberg, J.; Gaciong, Z.; Swedenborg, J.; Hedin, U. Fucoidan Inhibits Smooth Muscle Cell Proliferation and Reduces Mitogen-Activated Protein Kinase Activity. *European Journal of Vascular and Endovascular Surgery* **2000**, *20*, 419–426, doi:10.1053/EJVS.2000.1220.

143. Sakagami, H.; Toguchi, M.; Premanathan, M.; Arakaki, R. Effect of Mangroves on Distribution, Diversity and Abundance of Molluscs in Mangrove Ecosystem: A Review View Project Peptide Substrates for Kinases View Project. **1998**.

144. Boopathy, N.S.; Kandasamy, K.; Subramanian, M.; You-Jin, J. Effect of Mangrove Tea Extract from Ceriops Decandra (Griff.) Ding Hou. on Salivary Bacterial Flora of DMBA Induced Hamster Buccal Pouch Carcinoma. *Indian Journal of Microbiology* **2011**, *51*, 338–344, doi:10.1007/S12088-011-0096-3/METRICS.

145. Kapil, A.; Sharma, S.; Wahidulla, S. Leishmanicidal Activity of 2-Benzoxazolinone from Acanthus Illicifolius in Vitro. *Planta Medica* **1994**, *60*, 187–188, doi:10.1055/S-2006-959449/BIB.

146. Alves, C.; Silva, J.; Pinteus, S.; Gaspar, H.; Alpoim, M.C.; Botana, L.M.; Pedrosa, R. From Marine Origin to Therapeutics: The Antitumor Potential of Marine Algae-Derived Compounds. *Frontiers in Pharmacology* 2018, *9*.

147. Khalifa, S.A.M.; Elias, N.; Farag, M.A.; Chen, L.; Saeed, A.; Hegazy, M.E.F.; Moustafa, M.S.; El-Wahed, A.A.; Al-Mousawi, S.M.; Musharraf, S.G.; et al. Marine Natural Products: A Source of Novel Anticancer Drugs. *Marine Drugs* 2019, *17*, 491.